Figure 5From: Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancerA, Mean tumor volumes and estimated ID8-Vegf tumor growth curves in control mice or mice treated with paclitaxel, SU5416 or combination. B, Estimated difference between the observed mean tumor volume in animals receiving combined paclitaxel/SU5416 therapy and a predicted tumor volume assuming additive effects to the two individual drugs with 95% confidence intervals.Back to article page